GoodRx Holdings, Inc.

GoodRx Holdings, Inc. is an American healthcare company that operates a telemedicine platform and a free-to-use website and mobile application. Its core business involves tracking prescription drug prices across more than 75,000 pharmacies in the United States and providing coupons for significant discounts on medications. The company's mission is to help Americans access the healthcare they need at an affordable price, aiming to build better ways for individuals to find the right care at the best cost. GoodRx is headquartered in Santa Monica, California.

Key offerings include prescription drug price comparison tools, discount coupons, and a subscription service called GoodRx Gold, which provides deeper savings. The company also provides telehealth services through GoodRx Care, enabling online consultations with licensed healthcare providers for various conditions and prescription needs. GoodRx has expanded its services to include condition-specific subscription plans and facilitates access to GLP-1 medications, such as semaglutide (Ozempic, Wegovy), through its platform and partnerships with pharmaceutical manufacturers.

Wendy Barnes was appointed President and CEO of GoodRx, effective January 1, 2025, bringing extensive experience from the pharmacy and medical benefit industry. Co-founders Trevor Bezdek and Doug Hirsch remain involved as board members. In recent news, GoodRx announced in May 2026 that it expanded its offerings to include access to the Ozempic® pill (oral semaglutide) for Type 2 Diabetes patients, providing discounted self-pay pricing. The company reported fourth-quarter 2025 revenues that exceeded analyst estimates, though its full-year 2026 revenue guidance was below forecasts. GoodRx is positioned as a leading platform for medication savings, connecting various stakeholders within the healthcare ecosystem.

Latest updates

GoodRx Adds Novo Nordisk's Oral Semaglutide to Savings Platform

Event summary

  • GoodRx is now offering self-pay pricing for Novo Nordisk’s oral semaglutide (Ozempic pill) at pharmacies nationwide.
  • The pill is available for $149-$299 per month depending on the dosage (1.5mg, 4mg, 9mg).
  • GoodRx is used by approximately 25 million consumers and over one million healthcare professionals annually.
  • GoodRx has facilitated over $100 billion in medication savings for Americans since 2011.

The big picture

This partnership signals GoodRx’s strategic shift towards becoming a broader consumer access platform, directly connecting patients with pharmaceutical manufacturers. Novo Nordisk’s inclusion of the oral semaglutide demonstrates a willingness to leverage third-party platforms to expand market reach and manage pricing, a trend likely to accelerate as branded medications face increasing scrutiny over cost. The move also reinforces GoodRx’s position as a critical intermediary in the prescription drug ecosystem, potentially increasing its influence over pricing and patient behavior.

What we're watching

Market Adoption
The uptake rate of the oral semaglutide will be a key indicator of Novo Nordisk’s success and GoodRx’s ability to drive patient adoption of new medications.
Pricing Pressure
Continued expansion of GoodRx’s offerings may intensify pricing pressure on pharmaceutical manufacturers, potentially impacting profit margins.
Platform Evolution
GoodRx’s stated ambition to evolve beyond a pricing solution will require demonstrating its ability to attract and retain both patients and pharmaceutical partners.
CID: 1984